JP2024529728A5 - - Google Patents

Info

Publication number
JP2024529728A5
JP2024529728A5 JP2024509302A JP2024509302A JP2024529728A5 JP 2024529728 A5 JP2024529728 A5 JP 2024529728A5 JP 2024509302 A JP2024509302 A JP 2024509302A JP 2024509302 A JP2024509302 A JP 2024509302A JP 2024529728 A5 JP2024529728 A5 JP 2024529728A5
Authority
JP
Japan
Prior art keywords
dosage form
capsule
form according
capsule dosage
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024509302A
Other languages
English (en)
Japanese (ja)
Other versions
JP7846211B2 (ja
JP2024529728A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/040653 external-priority patent/WO2023023192A1/en
Publication of JP2024529728A publication Critical patent/JP2024529728A/ja
Publication of JP2024529728A5 publication Critical patent/JP2024529728A5/ja
Priority to JP2026060887A priority Critical patent/JP2026126211A/ja
Application granted granted Critical
Publication of JP7846211B2 publication Critical patent/JP7846211B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024509302A 2021-08-19 2022-08-17 治療適用のためのd-リゼルグ酸ジエチルアミドの即時放出製剤 Active JP7846211B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026060887A JP2026126211A (ja) 2021-08-19 2026-04-02 治療適用のためのd-リゼルグ酸ジエチルアミドの即時放出製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163234773P 2021-08-19 2021-08-19
US63/234,773 2021-08-19
PCT/US2022/040653 WO2023023192A1 (en) 2021-08-19 2022-08-17 IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026060887A Division JP2026126211A (ja) 2021-08-19 2026-04-02 治療適用のためのd-リゼルグ酸ジエチルアミドの即時放出製剤

Publications (3)

Publication Number Publication Date
JP2024529728A JP2024529728A (ja) 2024-08-08
JP2024529728A5 true JP2024529728A5 (cg-RX-API-DMAC7.html) 2025-10-10
JP7846211B2 JP7846211B2 (ja) 2026-04-14

Family

ID=85239753

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2024509301A Active JP7856745B2 (ja) 2021-08-19 2022-08-17 治療適用のためのd-リゼルグ酸ジエチルアミドの凍結乾燥された口腔内崩壊錠製剤
JP2024509302A Active JP7846211B2 (ja) 2021-08-19 2022-08-17 治療適用のためのd-リゼルグ酸ジエチルアミドの即時放出製剤
JP2026060887A Pending JP2026126211A (ja) 2021-08-19 2026-04-02 治療適用のためのd-リゼルグ酸ジエチルアミドの即時放出製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2024509301A Active JP7856745B2 (ja) 2021-08-19 2022-08-17 治療適用のためのd-リゼルグ酸ジエチルアミドの凍結乾燥された口腔内崩壊錠製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026060887A Pending JP2026126211A (ja) 2021-08-19 2026-04-02 治療適用のためのd-リゼルグ酸ジエチルアミドの即時放出製剤

Country Status (8)

Country Link
US (7) US20230064429A1 (cg-RX-API-DMAC7.html)
EP (2) EP4387624A4 (cg-RX-API-DMAC7.html)
JP (3) JP7856745B2 (cg-RX-API-DMAC7.html)
AU (4) AU2022331315B2 (cg-RX-API-DMAC7.html)
CA (2) CA3228975A1 (cg-RX-API-DMAC7.html)
IL (2) IL310591A (cg-RX-API-DMAC7.html)
TW (3) TWI838826B (cg-RX-API-DMAC7.html)
WO (2) WO2023023182A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4329759A4 (en) 2021-04-30 2025-07-16 Mind Medicine Inc CRYSTALLINE FORMS OF LSD SALTS
US12611399B2 (en) 2021-05-04 2026-04-28 Definium Therapeutics US, Inc. Movement disorders
US20230064429A1 (en) 2021-08-19 2023-03-02 Mind Medicine, Inc. IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
WO2025064381A1 (en) * 2023-09-18 2025-03-27 Phathom Pharmaceuticals Inc. Method for preparing vonoprazan with reduced nitrosamine
CN117224540B (zh) * 2023-11-08 2026-07-10 迪沙药业集团有限公司 一种盐酸多奈哌齐的药物组合物
WO2025128594A1 (en) * 2023-12-11 2025-06-19 Mind Medicine, Inc. Methods of treating generalized anxiety disorder

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1394233A (en) 1921-10-18 Arthur stoll
US2438259A (en) 1948-03-23 D-lysergic acid diethyl amide
US2774763A (en) 1956-12-18 Preparation of amides of lysergic age
US3085092A (en) 1963-04-09 Preparation of lysergic acid deriva-
US2090429A (en) 1937-08-17 Lysergic acid hydkazide and a
US2447214A (en) 1948-08-17 Hoocxchoxxchoxxcooh
US2090430A (en) 1937-08-17 Lysergic acid amides and process for
US2265207A (en) 1941-12-09 D-lysergic acid - d - l-bjtdroxybutyl
GB579484A (en) 1943-04-30 1946-08-06 Sandoz Ltd Process for the preparation of diethylamide of d-lysergic acid
US2809920A (en) 1953-04-10 1957-10-15 Saul & Co Process for the preparation of ergotamine, ergotaminine and ergometrine by saprophytic culture of ergot (claviceps purpurea [fr] tul.) in vitro and isolation of the alkaloids thus produced
US2796419A (en) 1954-09-27 1957-06-18 Lilly Co Eli Lysergic acid, intermediates and preparation
US2736728A (en) 1954-12-06 1956-02-28 Lilly Co Eli Preparation of lysergic acid amides
US2997470A (en) 1956-03-05 1961-08-22 Lilly Co Eli Lysergic acid amides
US3038840A (en) 1959-07-07 1962-06-12 Farmaceutici Italia Process for the production of alkaloid derivatives of lysergic acid
FR1338023A (fr) 1962-10-15 1963-09-20 Farmaceutici Italia Nouveau procédé de préparation d'amides d'acide lysergique, substituées ou non
US3239530A (en) 1964-01-13 1966-03-08 Sandoz Ltd Process for lysergic acid hydrazides
CH535236A (de) 1970-06-19 1973-03-31 Sandoz Ag Verfahren zur Herstellung neuer reaktionsträger Lysergsäurederivate
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5167616A (en) 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
US5225182A (en) 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
US5738875A (en) 1994-10-28 1998-04-14 R.P. Scherer Corporation Process for preparing solid pharmaceutical dosage forms
US6063908A (en) 1996-07-02 2000-05-16 Roche Diagnostics Corporation Reagents for lysergic acid diethylamide immunoassay
US20020028942A1 (en) 1997-01-15 2002-03-07 Jacewicz Victor Witold Novel process and compound
UA57859C2 (uk) 1998-10-14 2003-07-15 Авентіс Фармасьютікалз Інк. СКЛАДНІ ЕФІРИ (+)-АЛЬФА-(2,3-ДИМЕТОКСИФЕНІЛ)-1-[2-(4-ФТОРФЕНІЛ)ЕТИЛ]-4-ПІПЕРИДИНМЕТАНОЛУ, СПОСІБ ЇХ ОТРИМАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, СПОСІБ ІНГІБУВАННЯ ДІЇ СЕРОТОНІНУ НА 5HT<sub>2A</sub> РЕЦЕПТОР, СПОСІБ ЛІКУВАННЯ
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
EP1248832A4 (en) 2000-01-21 2004-07-07 Variagenics Inc IDENTIFICATION OF THE GENETIC COMPONENTS OF A MEDICINE REACTION
US6794496B2 (en) 2000-04-07 2004-09-21 Roche Diagnostics Corporation Immunoassay for LSD and 2-oxo-3-hydroxy-LSD
WO2002069933A1 (fr) * 2001-03-06 2002-09-12 Kyowa Hakko Kogyo Co., Ltd. Comprimés à délitement rapide dans la bouche
DE60239042D1 (de) 2001-12-20 2011-03-10 Randox Lab Ltd Haptene, Immunogene, Antikörper und Konjugate für 2-oxo-3-hydroxy LSD
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US8401801B2 (en) 2003-02-20 2013-03-19 Mayo Foundation For Medical Education And Research Methods for selecting medications
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
WO2005115473A2 (en) 2004-05-24 2005-12-08 Nutrinia Ltd. Nutritional food and feed, composition, processing and method of use
EP1781272B1 (en) 2004-07-24 2017-09-06 Laboratorios Del Dr. Esteve, S.A. Use of compounds active on the sigma receptor for the treatment of mechanical allodynia
US20060039890A1 (en) 2004-08-20 2006-02-23 Renshaw Perry F Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant
JP2006124282A (ja) 2004-10-26 2006-05-18 Central Glass Co Ltd 3,3,3−トリフルオロプロピオン酸の製造方法
US20060167481A1 (en) 2005-01-25 2006-07-27 Esophyx, Inc. Slitted tissue fixation devices and assemblies for deploying the same
US20060223998A1 (en) 2005-03-30 2006-10-05 Fang-Jie Zhang Synthetic LSD metabolite for preparing haptens used in an LSD metabolite immunoassay
GB0511060D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
CA2650498A1 (en) * 2006-03-31 2007-10-11 Rubicon Research Private Limited Orally disintegrating tablets
WO2008116024A2 (en) 2007-03-19 2008-09-25 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
CN101686942B (zh) 2007-06-27 2012-09-26 韩美药品株式会社 用于快速制备用于口服的崩解剂的方法及其产品
JP5450435B2 (ja) 2007-11-30 2014-03-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ヘテロアリールで置換されたピペリジン類
US9642819B2 (en) 2008-07-10 2017-05-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical Low dosage serotonin 5-HT2A receptor agonist to suppress inflammation
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
BRPI0918623A2 (pt) 2008-09-17 2015-12-01 Hannover Med Hochschule métodos e kits para tratar distúrbios de cefaleia em grupo
ES2607209T3 (es) 2009-02-06 2017-03-29 Egalet Ltd. Composiciones farmacéuticas resistentes al abuso
US10548839B2 (en) * 2010-03-16 2020-02-04 Wei Tian Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form
US20120108510A1 (en) 2010-05-20 2012-05-03 Emory University Methods of improving behavioral therapies
WO2012058769A1 (en) 2010-11-03 2012-05-10 Mcmaster University Method of treating mucosal inflammation
WO2014059197A1 (en) 2012-10-10 2014-04-17 Henkin Robert I Methods and compositions for diagnosing and treating hyposmia
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
US20170253928A1 (en) 2013-03-15 2017-09-07 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
US20140274764A1 (en) 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
US10118006B2 (en) 2014-06-30 2018-11-06 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
US10098854B2 (en) 2014-08-13 2018-10-16 Janssen Pharmaceutica Nv Method for the treatment of depression
EP2990029A1 (en) 2014-08-29 2016-03-02 Sandoz Ag Pharmaceutical compositions comprising Canagliflozin
ES2985064T3 (es) 2015-01-28 2024-11-04 Univ Duke Composición que comprende metilfenidato y ondansetrón para su uso en trastornos relacionados con la toxicomanía
EP3268086A4 (en) * 2015-03-10 2018-11-07 Eleusis Benefit Corporation, PBC Lsd for the treatment of alzheimer's disease
US20180105876A1 (en) 2015-04-18 2018-04-19 Baycrest Technology Pty Ltd Medication dosing report
DK3334709T3 (da) 2015-08-12 2025-02-03 Incyte Holdings Corp Salte af en lsd1-hæmmer
WO2017066488A1 (en) 2015-10-13 2017-04-20 Charleston Laboratories, Inc. Treating pain using a composition comprising an opioid and an antiemetic
US20210069170A1 (en) 2016-07-23 2021-03-11 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
US20200222656A1 (en) 2016-10-18 2020-07-16 Joseph Rustick Method for treatment of depression using synaptic pathway training
NL2018190B1 (en) 2017-01-18 2018-07-26 Procare Beheer B V Psilocybin or psilocin in combination with cannabinoid
US11974984B2 (en) 2017-02-09 2024-05-07 Caamtech, Inc. Compositions and methods comprising a combination of serotonergic drugs
US20190142851A1 (en) 2017-11-16 2019-05-16 CaaMTech, LLC Compositions comprising a psilocybin derivative and a cannabinoid
CA3057994A1 (en) 2017-03-30 2018-10-04 Ojai Energetics Pbc A unit dose or mixture comprising carboxylated and decarboxylated cannabinoids
US20200147038A1 (en) 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
US11471415B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
WO2019079742A1 (en) 2017-10-19 2019-04-25 Eleusis Benefit Corporation, Pbc METHODS AND SYSTEMS FOR IMPROVING THE SAFETY OF PSYCHEDELIC PHARMACOTHERAPIES
US11723894B2 (en) 2017-10-26 2023-08-15 Terran Biosciences, Inc. Combination product for the treatment of neurological and/or psychiatric disorders
EP3707275A4 (en) 2017-11-07 2021-11-10 Medreleaf Corp. DOSAGE AND VARIETY RECOMMENDATIONS FOR THE TREATMENT OF DISEASES USING CANNABIS
US11367103B2 (en) 2020-03-02 2022-06-21 Yieldmo, Inc. Method for modeling digital advertisement consumption
EP3813810A4 (en) 2018-06-21 2022-03-30 Robert John Petcavich METHODS OF INDUCING DENDRITICAL AND SYNAPTIC GENESIS IN CHRONIC NEURODEGENERATIVE DISEASES
WO2020024977A1 (zh) 2018-08-01 2020-02-06 陕西麦科奥特科技有限公司 用于治疗神经系统疾病的化合物及其应用
MX2021009037A (es) 2019-01-30 2021-10-13 Diamond Therapeutics Inc Composiciones y metodos para el manejo de trastornos.
HUE066828T2 (hu) 2019-02-22 2024-09-28 Gh Res Ireland Limited 5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére
US12616706B2 (en) 2019-03-07 2026-05-05 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
WO2020216832A1 (en) 2019-04-24 2020-10-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the response of antipsychotic drugs
WO2020232255A1 (en) 2019-05-14 2020-11-19 The Scripps Research Institute Compounds for the treatment of neurodegenerative and metabolic disorders
WO2021003467A1 (en) 2019-07-04 2021-01-07 Sw Holdings, Inc. Metered dosing compositions and methods of use of psychedelic compounds
US20210015738A1 (en) * 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
GB201911024D0 (en) 2019-08-01 2019-09-18 Beckley Found Compounds for use in a method of treating or preventing neurological and/or psychiatric disorders
WO2021030571A1 (en) 2019-08-13 2021-02-18 University Of Maryland, Baltimore Methods of treating psychological and brain disorders
US11246860B2 (en) 2019-11-07 2022-02-15 Lophora ApS 5-HT2A agonists for use in treatment of depression
IL295671A (en) 2020-02-28 2022-10-01 Universit?Tsspital Basel Controlling effects after 5ht2a agonists administration
GB202003059D0 (en) 2020-03-03 2020-04-15 Beckley Found Compounds for use in a method of treating, preventing and/or reducing the symptoms of pain
CN115916173A (zh) 2020-04-13 2023-04-04 巴塞尔大学医院 Lsd剂量鉴定
CA3173048A1 (en) 2020-04-16 2021-10-21 Fotios M. Plakogiannis Transdermal micro-dosing delivery of psychedelics derivatives
EP4142693A1 (en) 2020-05-01 2023-03-08 Emergex USA Corporation Transdermal drug delivery devices having psilocybin, lysergic acid diethylamide or 3,4-methylenedioxymethamphetamine coated microprotrusions
AU2021267101B2 (en) 2020-05-05 2024-03-28 Universitätsspital Basel MDMA treatment to enhance acute emotional effects profile of LSD, psilocybin or other psychedelics
WO2021243461A1 (en) 2020-06-04 2021-12-09 Neonmind Biosciences Inc. Use of lsd, esa, or dmt for weight loss.
AU2021292943B2 (en) 2020-06-15 2024-04-04 Universitätsspital Basel MDMA response prediction
EP4167992A1 (en) 2020-06-22 2023-04-26 University of Zürich Compositions and kits of parts comprising n,n-dimethyltryptamine and harmine and their use in therapy
US20210407643A1 (en) 2020-06-25 2021-12-30 Greenway Dna Inc. Methods and systems for providing a personalized treatment regimen using cannabinoid or psychedelic compounds
WO2022008627A2 (en) 2020-07-07 2022-01-13 Compass Pathfinder Limited Improved method for the production of lysergic acid diethylamide (lsd) and novel derivatives thereof
EP4188382A4 (en) 2020-07-29 2024-08-14 The Royal Institution for the Advancement of Learning / McGill University Administration of modulators of 5-ht and/or ampa receptors for treating neurological conditions
WO2022023812A1 (en) 2020-07-29 2022-02-03 Diamond Therapeutics Inc. Extended release 5-ht receptor agonists for neurological conditions
WO2022030571A1 (ja) 2020-08-06 2022-02-10 株式会社一志精工電機 金型構造、プレス加工装置、およびプレス加工方法
DE202020105085U1 (de) 2020-09-03 2020-11-30 Sophie-Charlotte Adler Therapiemethode in Kombination mit psychoaktiver Zusammensetzung
EP4222501A1 (en) 2020-10-24 2023-08-09 Universitätsspital Basel Method of quantifying lysergic acid diethylamide (lsd) and 2,3-dihydro-3-hydroxy-2-oxo lysergide (o-h-lsd) in human plasma
WO2022107095A1 (en) 2020-11-22 2022-05-27 Havn Life Sciences Inc. Methods and compositions for treating pain with 2-bromo-lysergic acid diethylamide and thymoquinone
WO2022115796A1 (en) 2020-11-30 2022-06-02 Wesana Health Inc. Compositions and methods for treating neurological conditions
WO2022120289A1 (en) 2020-12-02 2022-06-09 The Johns Hopkins University Restoration of motor function post-neurological injury using psychedelics
EP4126857A1 (en) 2021-01-15 2023-02-08 Beckley Psytech Limited Ergoline analogues
US20220273628A1 (en) 2021-02-19 2022-09-01 Universitätsspital Basel Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness
BR112023017866A2 (pt) 2021-03-06 2023-10-10 Univ Basel Método de dosagem de lsd no tratamento de pacientes, método para determinar uma dose preferida de lsd e método para determinar uma dose de lsd com base na avaliação da presença de inibidores de cyp2d6
KR20240006525A (ko) 2021-03-31 2024-01-15 라이프 씨에이치엔지 엘엘씨 환각제의 치료적 투여를 위한 경피 시스템, 제제 및 방법
WO2022221942A1 (en) 2021-04-19 2022-10-27 Betterlife Pharma Inc. Prevention of drug diversion
IL307880A (en) 2021-04-23 2023-12-01 Gilgamesh Pharmaceuticals Inc New ergolines and methods for treating mood disorders
US20230116703A1 (en) 2021-04-23 2023-04-13 Gilgamesh Pharmaceuticals, Inc. Novel ergolines and methods of treating mood disorders
EP4329759A4 (en) 2021-04-30 2025-07-16 Mind Medicine Inc CRYSTALLINE FORMS OF LSD SALTS
US20220362237A1 (en) 2021-05-03 2022-11-17 Mind Medicine, Inc. Psychedelics for treatment of pain
EP4333979A4 (en) 2021-05-03 2025-01-15 Mind Medicine, Inc. Method of titrating dose of psychedelics
US20220347195A1 (en) 2021-05-03 2022-11-03 Mind Medicine, Inc. Psychedelics for treatment of pain
US12611399B2 (en) 2021-05-04 2026-04-28 Definium Therapeutics US, Inc. Movement disorders
US20230301985A1 (en) 2021-05-04 2023-09-28 Mind Medicine, Inc. Movement disorders
WO2022246572A1 (en) * 2021-05-26 2022-12-01 Mindset Pharma Inc. Hallucinogen-fatty acid combination
WO2022261058A1 (en) 2021-06-07 2022-12-15 University Of Mississippi Methods for the pulsed delivery of bioactive agents
WO2022265878A1 (en) 2021-06-14 2022-12-22 Mind Medicine, Inc. Controlling effects after 5ht2a agonists administration
WO2023283386A2 (en) 2021-07-07 2023-01-12 Arcadia Medicine, Inc. Safer psychoactive compositions
US20230059204A1 (en) 2021-08-03 2023-02-23 Pike Therapeutics, Inc. Transdermal micro-dosing delivery of pharmaceutical agents
WO2023012524A2 (en) 2021-08-03 2023-02-09 Universitatsspital Basel Lsd and psilocybin dose equivalence determination
US20230064429A1 (en) 2021-08-19 2023-03-02 Mind Medicine, Inc. IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
WO2023043870A1 (en) 2021-09-15 2023-03-23 Eleusis Therapeutics Us, Inc. Chewing gum formulation of lsd and methods of use thereof
US20230219955A1 (en) 2021-09-20 2023-07-13 Betterlife Pharma Inc. Lsd derivatives, synthesis & method for treatment of diseases and disorders
WO2023107966A1 (en) 2021-12-06 2023-06-15 Terran Biosciences, Inc. Salt and solid forms of lysergic acid diethylamide (lsd) and analogs
WO2023108277A1 (en) 2021-12-14 2023-06-22 Agile Pharmaceuticals Solutions Inc. Cannabinoid and psychedelic formulations comprising hydrotropic agents
EP4448518A4 (en) 2021-12-16 2025-12-17 Terran Biosciences Inc ISOTOPICALLY ENRICHED ANALOYS OF 2-BROM-LSD, LSD, ALD-52 AND 1P-LSD
WO2023114529A2 (en) 2021-12-17 2023-06-22 Bennes, Inc. Pharmacoactive formulations for delivery of psychedelic compounds
EP4499109A1 (en) 2022-03-25 2025-02-05 Ojai Energetics PBC Psychedelic compositions and methods for forming the same
US20250295611A1 (en) 2022-04-27 2025-09-25 Tessellate Therapeutics Inc. Methods of treating 5ht2a receptor-mediated conditions
US20230346645A1 (en) 2022-05-01 2023-11-02 Mind Medicine, Inc. Method of titrating dose of psychedelics
CN119923261A (zh) 2022-06-20 2025-05-02 思维医学股份有限公司 具有改良的lsd样作用的麦角酸衍生物
US20260034058A1 (en) 2022-08-09 2026-02-05 Vitalmelt Ltd. Freeze-dried bite with single dose psychedelic
JP2026515993A (ja) 2023-05-04 2026-05-19 ギルガメッシュ・ファーマシューティカルズ・インコーポレイテッド 新規エルゴリン及び気分障害を処置する方法
WO2024238035A1 (en) 2023-05-16 2024-11-21 Mind Medicine, Inc. Movement disorders
WO2024263978A1 (en) 2023-06-22 2024-12-26 Mind Medicine, Inc. Allyl- and propargylamine-type phenethylamines and tryptamines for treating medical disorders
WO2025128594A1 (en) 2023-12-11 2025-06-19 Mind Medicine, Inc. Methods of treating generalized anxiety disorder

Similar Documents

Publication Publication Date Title
ES2261234T5 (es) Metabolitos de bupropion y metodos de sintesis y uso.
JP2024529727A5 (cg-RX-API-DMAC7.html)
RU2317817C2 (ru) Применение (1s,2r) энантиомера милнаципрана для получения лекарственного средства
TWI294779B (en) Use of optically pure (s,s)-reboxetine in the manufacture of a medicament for the treatment or prevention of peripheral neuropathy
CN114340670B (zh) T-型钙通道调节剂的制剂及其使用方法
JP4664505B2 (ja) ビュープロピオン代謝物質ならびにその合成方法および使用
US8309535B2 (en) Compositions and methods to treat recurrent medical conditions
JP2020536873A (ja) 迅速発現作用延長型の植物系及び合成カンナビノイド製剤
JP2021519267A5 (cg-RX-API-DMAC7.html)
JP2005539068A5 (cg-RX-API-DMAC7.html)
JP2021525729A5 (cg-RX-API-DMAC7.html)
CN118576586A (zh) 治疗神经和精神疾病的方法
JP2022153638A5 (cg-RX-API-DMAC7.html)
JP2022515766A5 (cg-RX-API-DMAC7.html)
JP2013544850A5 (cg-RX-API-DMAC7.html)
JP5864819B2 (ja) 精神的障害、行動障害および認知障害の予防および治療のための医薬組成物
CN106727439A (zh) 一种盐酸美金刚缓释‑多奈哌齐速释复方胶囊
JP2022539152A5 (cg-RX-API-DMAC7.html)
WO2016101898A1 (zh) 3-[(苯并[d][1,3]二氧戊环-4-基)-氧基]-3-芳基丙胺类化合物及其应用
JP2020531543A (ja) アマンタジン組成物、その調製、および使用方法
CN102488681A (zh) 布洛芬苯海拉明口腔崩解片及其制备方法
WO2016127123A2 (en) Compounds and methods for preventing or treating sensory hair cell death
CN109200051A (zh) 石杉碱甲及其类似物作为治疗炎症性疾病药物的用途
EP2958550B1 (en) Oral formulation and suspension of an oncology drug
CA2460348A1 (en) Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites